½üÄêÀ´£¬È«Çò·ÊÅÖÖ¢»¼²¡ÂÊÒ»Á¬ÉÏÉý£¬·ÊÅÖ¼°Ïà¹Ø´úл×ÛºÏÕ÷ÏÔÖøÔöÌíÁËÌÇÄò²¡¡¢ÐÄѪ¹Ü¼²²¡µÈ¶àÖÖÂýÐÔ²¡µÄ±¬·¢Î£º¦¡£Òò´Ë£¬Ö¬·¾×éÖ¯×÷ΪÈËÌåÖ÷ÒªÄÚÉøÍ¸Æ÷¹Ù£¬Æä¹¦Ð§×´Ì¬±¸ÊܹØ×¢¡£Ïà¹ØÑо¿·¢Ã÷£¬Ö¬ÁªËØÊÇÖ¬·¾×éÖ¯ÌØÒìÐÔÉøÍ¸µÄÒªº¦Ï¸°ûÒò×Ó£¬ÑªÒºÖÐÖ¬ÁªËØË®Æ½µÄת±ä£¬ÓÌÈçѸËٵġ°¾¯±¨Æ÷¡±£¬ÄÜΪÎÒÃÇÕ¹ÏÖ¶àÖÖÂýÐÔ¼²²¡µÄDZÔÚΣº¦ºÍÉú³¤×´Ì¬¡£
ʲôÊÇÖ¬ÁªËØ£¿
Ö¬ÁªËØ£¨ADPN£©ÊÇÓÉÖ¬·¾Ï¸°ûÉøÍ¸µÄÄÚÔ´ÐÔÉúÎï»îÐÔ¶àëÄ»òÂѰ×ÖÊ£¬ÔÚÉíÌå´úлÖÐÊÎÑÝ×ÅÖÁ¹ØÖ÷ÒªµÄ½ÇÉ«£¬Ö÷Òª×÷ÓÃÓÚ¸ÎÔࡢѪ¹ÜºÍÒÈÏÙµÈ×éÖ¯£¬Ê©Õ¹ÒȵºËØÔöÃô¡¢½µÑªÌǺͿ¹Ñ×µÈÒªº¦µ÷Àí×÷Óã¬ÊÇÒ»Öֶ๦Чµ÷Àí¼Á£Û1-2£Ý¡£
Ö¬ÁªËØÓë³£¼û¼²²¡µÄ¹ØÁª
1.·ÊÅÖ
Ö¬ÁªËØÊÇÏÖÔÚÒÑÖªÓë·ÊÅֳʸºÏà¹ØµÄϸ°ûÒò×Ó¡£³¬ÖØ·ÊÅÖ»¼ÕßµÄÖ¬·¾Ñõ»¯¹¦Ð§½ÏÈõ£¬ÌÇ´úл¹¦Ð§¼õÍË£¬Í¬Ê±»¹ÃæÁÙ×ÅÑ×Ö¢¼°¶¯ÂöÖàÑùÓ²»¯µÄΣº¦£¬Ö÷ÒªÊÇÆäÌåÄÚÖ¬ÁªËØË®Æ½µÍÓÚÕý³£ÌåÖÊÁ¿ÈËȺ£¬µ¼ÖÂÖ¬ÁªËØÎÞ·¨³ä·ÖÑéÕ¹×÷ÓãÛ6-7£Ý¡£
ͬʱ£¬Indulekha K¡¢Surendar J¡¢Anjana R MµÈÓ¡¶ÈѧÕߣÛ8£ÝÑо¿Ö¤Êµ£¬Ö¬ÁªËØÓë·ÊÅÖÈËȺµÄ´úл״̬Ç×½üÏà¹Ø,µÍÖ¬ÁªËØË®Æ½»áÔöÌí·ÊÅÖÈËȺ·ºÆð´úлÒì³£¡¢¸ßѪѹ¼°¸ßÈýõ£¸ÊÓÍѪ֢µÄΣº¦¡£Ö¬ÁªËØ¿Éͨ¹ýÓÕµ¼Ñªáú½éÃܶÈÖ¬ÂѰ׵¨¹Ì´¼£¨HDL-C£©Éý¸ß¡¢¸ÊÓÍÈýõ¥£¨TG£©ïÔÌÀ´¸ÄÉÆÖ¬´úл£¬»¹¿Éͨ¹ý»Ö¸´Ö¬·¾×éÖ¯ÉøÍ¸Ö¬ÁªËصÄÄÜÁ¦£¬¾ÀÕý´úлÔÓÂÒ£¬½ø¶ø½µµÍ·ÊÅÖÏà¹ØÂýÐÔ²¡µÄ·¢²¡Î£º¦£Û9£Ý¡£
2.ÌÇÄò²¡
´ó×ÚÑо¿Ö¤Êµ£¬ÌÇÄò²¡·¢²¡Î£º¦ÓëÖ¬ÁªËØË®Æ½³ÊÏÔÖø¸ºÏà¹Ø¡£Ö¬ÁªËØÖ÷Ҫͨ¹ýÌá¸ßÒȵºËØÃô¸ÐÐÔ£¬ÔöÇ¿ÒȵºËØÒÖÖÆÌÇÔÒìÉúµÄ×÷Óã¬ÒÖÖÆ¸ÎÌÇÔÌìÉú£¬ÊÇά³Ö»úÌåѪ֬ѪÌÇÎȹ̵ÄÖ÷Òªµ÷ÀíÒò×Ó¡£

Ö¬ÁªËØË®Æ½½µµÍ»á¼Ó¾çÒȵºËضԿ¹£¬Éý¸ßÌÇÄò²¡Î£º¦£¬¸üΪҪº¦µÄÊÇ£¬Ö¬ÁªËØË®Æ½µÄת±äÍùÍùÔçÓÚѪÌÇÉý¸ß£¬ÊÇÌÇÄò²¡±¬·¢µÄÖ÷ÒªÔçÆÚÔ¤¾¯ÐźÅÖ®Ò»¡£Òò´Ë£¬Ö¬ÁªËØ¿É×÷Ϊ·¢Ã÷¡¢Õï¶Ï2ÐÍÌÇÄò²¡£¨T2DM£©¸ßΣº¦¸öÌå¼°¼à²â¼²²¡Ï£ÍûµÄÖ¸±ê£Û2-3£Ý¡£

Ö¬ÁªËØÕ¹ÍûÌÇÄò²¡Î£º¦¿µ½¡¹ÜÀí½¨Òé
3.ÐÄѪ¹Ü¼²²¡
Ö¬ÁªËؾßÓп¹¶¯ÂöÖàÑùÓ²»¯¡¢¿¹¸ßѪÌǼ°¿¹Ñ×Ö¢µÈ¶àÖÖ×÷Óã¬ÓÚ´úл¼°¶¯ÂöÖàÑùÓ²»¯Àú³ÌÒâÒåÖØ´ó£¬ÊÇÆÀ¹ÀÐÄѪ¹Ü¼²²¡Î£º¦µÄÐÂÐ˱ê¼ÇÎïÖ®Ò»¡£
¶¯ÂöÖàÑùÓ²»¯ÊÇÐÄѪ¹Ü¼²²¡µÄÖ÷Òª²¡Àí»ù´¡£¬µ±Ö¬ÁªËØÈ±·¦Ê±£¬Ñª¹ÜÄڱڵġ°±£»¤Ä¤¡±»á±ä±¡£¬¸üÒ×ÊÜË𣬵¼Ö°߿éÐÎ³ÉºÍÆÆË飬ÔöÌíÐ£ËÀ¡¢ÖзçµÈÐÄѪ¹ÜÊÂÎñµÄ±¬·¢Î£º¦¡£Ïà¹ØÑо¿·¢Ã÷£¬¼±ÐÔÐ£ËÀ£¨AMI£©»¼ÕßѪÇåÖ¬ÁªËØË®Æ½»áϽµ£¬¸Ãת±äÓë²»Á¼Ô¤ºóÏà¹Ø£¬ÊÇÕ¹ÍûAMIºó±¬·¢ÐÄÁ¦Ë¥½ß£¨HF£©¼°Ö÷Òª²»Á¼ÐÄѪ¹ÜÊÂÎñ£¨MACE£©µÄÓмÛÖµÖ¸±ê£Û4£Ý¡£¾Ýͳ¼Æ£¬¼±ÐÔAMI»¼Õß½ÓÊܾƤ¹Ú×´¶¯Âö½éÈëÊõ£¨PCI£©ºó2¡¢3ÄêµÄMACE±¬·¢ÂÊ»®·ÖΪ16%ºÍ20%£Û5£Ý£¬¿É¼û£¬ÑªÇåÖ¬ÁªËØÕ¹ÍûHFºÍMACEµÄ¼ÛÖµÏÔÖø¡£
4.·Ç¾Æ¾«ÐÔÖ¬·¾¸Î
·Ç¾Æ¾«ÐÔÖ¬·¾¸Î²¡£¨NAFLD£©ÊÇÒÔ¸Îϸ°ûÖ¬·¾³Á»ý¡¢±äÐÔΪ²¡ÀíÌØÕ÷µÄ³£¼ûÂýÐԸβ¡¡£Ïà¹ØÊý¾ÝÏÔʾ£Û10£Ý£¬È«ÇòNAFLDÊ¢ÐÐÂÊ´ï30%£¬ÇÒÈÔÔÚÒ»Á¬ÉÏÉý¡£ÓÐÎÄÏ×Ö¸³ö£Û11£Ý£¬µÍÖ¬ÁªËØÑªÖ¢¿ÉÄÜÔÚNAFLDÏò·Ç¾Æ¾«ÐÔÖ¬·¾¸ÎÑ×Ï£ÍûµÄÀú³ÌÖÐʩչÖ÷Òª×÷Óã¬ÓÐÍû³ÉΪδÀ´NAFLDÕïÁƵÄDZÔÚÊÓ²ìµã¡£ÑªÇåµÍÖ¬ÁªËØË®Æ½ÓëNAFLD±¬·¢¼°ÌÇÖ¬´úл¡¢¸Î¹¦Ð§Òì³£Ïà¹Ø£¬¿É×÷ΪNAFLDDZÔÚÕ¹ÍûÖ¸±ê£¬µ«Ïà¹Ø½áÂÛÈÔÐè½øÒ»²½Ñо¿ÑéÖ¤¡£
5.¶àÄÒÂѳ²×ÛºÏÕ÷
¼ÈÍùÑо¿Åú×¢£¬¶àÄÒÂѳ²×ÛºÏÕ÷(PCOS)»¼ÕßµÄѪÇåÄòËáˮƽ¸ßÓÚ·ÇPCOS»¼ÕߣÛ12£Ý,¶øÑªÇåÖ¬ÁªËØË®Æ½ÔòÏà¶Ô½µµÍ¡£ÄòËá×÷ΪàÑßÊ´úлµÄÖÕ²úÆ·ÓëÖ¬ÁªËسʸºÏà¹Ø¡£Ö¬ÁªËؾßÓÐÒȵºËØÑù×÷Óã¬Äܹ»µ÷¿ØÈËÌåÄÚµÄÄÜÁ¿Æ½ºâ£¬Æäˮƽת±äÔÚPCOSµÄ±¬·¢Éú³¤Öб¬·¢Ö÷ÒªÓ°Ïì¡£PCOSÊÇÓýÁäÆÚÅ®ÐÔ³£¼ûµÄÉúÖ³ÄÚÉøÍ¸´úлÒì³£¼²²¡£¬Æä±¬·¢Éú³¤µÄϸ°û·Ö×Óѧ»úÖÆÉÐδÍêÈ«ÆÊÎö¡£Ñ»·ÑªÖÐÖ¬ÁªËØË®Æ½½µµÍÊÇPCOS»¼Õß³£¼ûµÄ´úлÒì³£ÌåÏÖ£¬Òò´Ë£¬¼ì²âÖ¬ÁªËØË®Æ½¹ØÓÚPCOSµÄÔçÆÚÔ¤·ÀºÍÖÎÁƾßÓÐÖ÷ÒªÒâÒå£Û13£Ý¡£
ÁÙ´²³£¼ûµÄÖ¬ÁªËØÎÊÌâ½â´ð
Q£ºÄÜͨ¹ý¼ì²âÖ¬ÁªËØË®Æ½À´ÅжÏÉíÌ念½¡×´Ì¬Âð£¿
A£º¿ÉÒÔ×÷Ϊ²Î¿¼ÐÅÏ¢¡£ÑªÒºÖеÄÖ¬ÁªËØ£¨ÓÈÆä¸ß·Ö×ÓÁ¿ÑÇÐÍ£©¿É×÷Ϊ´úл¿µ½¡µÄÉúÎï±ê¼ÇÎµÍÖ¬ÁªËØÍ¨³£ÌáÐÑ2ÐÍÌÇÄò²¡¡¢ÐÄѪ¹Ü¼²²¡µÄ·¢²¡Î£º¦½Ï¸ß¡£µ«¼ì²âЧ¹ûÐèÍŽáÆäËûÖ¸±ê×ÛºÏÅжϣ¬²»¿Éµ¥¶À×÷Ϊ¿µ½¡×´Ì¬µÄΨһÆÀÅÐÒÀ¾Ý¡£
Q£ºÍ¨Ë×ÈËÐèÒª¼ì²âÖ¬ÁªËØË®Æ½Âð£¿
A£ºÒ»Ñùƽ³£ÈËȺ¿É½«Ö¬ÁªËؼì²âÄÉÈëͨÀýÌå¼ì£¬ÓÃÓÚÆÀ¹À×ÔÉí´úл¿µ½¡×´Ì¬¡£ÌØÊâ¹ØÓÚ·ÊÅÖ¡¢ÌÇÄò²¡¸ßΣÈËȺ£¨ÈôÓмÒ×åÊ·¡¢¿Õ¸¹ÑªÌÇÆ«¸ßÕߣ©ÒÔ¼°ÐÄѪ¹Ü¼²²¡»¼Õß¶øÑÔ£¬¼ì²âÖ¬ÁªËؿɸ¨ÖúÆÀ¹À´úлΣº¦£¬ÎªÂýÐÔ¼²²¡µÄ¸ÉÔ¤Ìṩ²Î¿¼ÒÀ¾Ý¡£
Q£ºµÍÖ¬ÁªËØË®Æ½£¬Ò»¶¨Òâζ×Å·ºÆðÁË¿µ½¡ÎÊÌâÂð£¿
A£º·×Æç¶¨¡£Ö¬ÁªËØË®Æ½ÊܶàÖÖÒòËØÓ°Ï죬ÈçÄêËê¡¢ÐÔ±ð¡¢Ô˶¯Ï°¹ßµÈ¡£µ¥´Î¼ì²âÆ«µÍʱ£¬ÐèÍŽáÌåÖØ¡¢ÑªÌÇ¡¢ÑªÖ¬µÈÖ¸±ê×ÛºÏÅжϡ£ÈôÅãͬÒȵºËضԿ¹¡¢Ö¬·¾¸ÎµÈÎÊÌ⣬ÔòÐèСÐÄ´úлÒì³£µÄ¿ÉÄÜ¡£
Q£ºÉíÌå״̬½ÏΪÏûÊݵÄÈËȺ£¬»á²»»áÓÐÖ¬ÁªËØË®Æ½½ÏµÍµÄÇéÐΣ¿
A£º¿ÉÄܻᡣËäȻ֬ÁªËØÓëÌåÖ¬³Ê¸ºÏà¹Ø£¬µ«²¿·ÖÊÝÈËȺÌåÓÉÓÚÒÅ´«ÒòËØ¡¢ÂýÐÔѹÁ¦»ò²»Á¼ÉúÑÄϰ¹ß£¨Èç¾Ã×ø²»¶¯¡¢ÓªÑø²»Á¼µÈ£©£¬Ò²¿ÉÄÜ·ºÆðÖ¬ÁªËØË®Æ½Æ«µÍµÄÇéÐΣ¬½ø¶ø±£´æ´úлΣº¦£¨ÈçÊÝËØ¶Ô¿¹£©¡£
Q£ºÖ¬ÁªËØË®Æ½¸ß£¬ÉíÌå¾ÍÒ»¶¨¿µ½¡Âð£¿
A£º·×Æç¶¨¡£ÉÙÉÙÊýÇéÐÎÏ£¨ÈçÑÏÖØ¼²²¡ÏûºÄ״̬£©£¬Ö¬ÁªËØË®Æ½¿ÉÄÜÒì³£Éý¸ß£¬ÐèÍŽáСÎÒ˽¼ÒÕûÌ念½¡×´Ì¬Åжϣ¬²¢·ÇÖ¬ÁªËØË®Æ½Ô½¸ßÔ½ºÃ¡£
Q£ºÖ¬ÁªËØË®Æ½»áËæ×ÅÄêËêµÄÔöÌí¶ø×ª±äÂð£¿
A£ºÓпÉÄÜ¡£Ëæ×ÅÄêËêÔöÌí£¬ÈËÌåÖ¬ÁªËØË®Æ½¿ÉÄÜ·ºÆð²¨¶¯£¬²¿·ÖÖÐÍíÄêÈ˵ÄÖ¬ÁªËØË®Æ½Æ«µÍ£¬ÕâÓë´úлÄÜÁ¦Ï½µÓйء£¼ÍÂÉÔ˶¯ÓÐÖúÓÚά³ÖÖ¬ÁªËØË®Æ½µÄÎȹ̡£
Q£ºËØÊ³ÕßÉíÌåÄÚµÄÖ¬ÁªËØË®Æ½¸ü¸ßÂð£¿
A£º·×Æç¶¨¡£²¿·ÖÑо¿ÏÔʾ£¬ºÏÀíËØÊ³¿ÉÄÜÓÐÖúÓÚά³Ö½Ï¸ßµÄÖ¬ÁªËØË®Æ½£¬Õâ¿ÉÄÜÓëËØÊ³ÒûʳÖи»º¬ÉÅʳÏËά¡¢²»±¥ºÍÖ¬·¾Ëá¡¢¿¹Ñõ»¯ÎïÖʵÈÒòËØÓйأ¬ÕâЩÒòËØÓÐÖúÓÚ¸ÄÉÆ´úл״̬£¬¼ä½ÓÔö½øÖ¬ÁªËصĺϳÉÓëÉøÍ¸¡£µ«ÕâÒ»½áÂÛµÄÌõ¼þÊÇ¡°ÓªÑøÆ½ºâ¡±µÄËØÊ³£¬¶ø·Ç´¿´â¡°²»³ÔÈ⡱µÄÒûʳģʽ¡£
Q£ºÔÐÆÚ£¬Ôи¾ÌåÄÚµÄÖ¬ÁªËØË®Æ½»áת±äÂð£¿
A£ºÔÔòÉϻᡣ֬ÁªËØË®Æ½ÔÚÔÐÆÚ¿ÉÄÜ·ºÆð²¨¶¯£¬ÓÈÆäÔÚÔÐÍíÆÚ¿ÉÄÜ»áϽµ¡£ÔÐÔçÆÚÖÁÖÐÆÚÏà¶ÔÎȹ̣¬ÀûÓÚά³ÖĸÌå´úлƽºâ¼°Ì¥¶ùÓªÑø¹©Ó¦£¬¶øµ½ÁËÔÐÍíÆÚ£¬Ëæ×ÅÌ¥¶ù¿ìËÙÉú³¤¡¢Ä¸ÌåÖ¬·¾´¢±¸ÔöÌíÒÔ¼°¼¤ËØË®Æ½£¨Èç´Æ¼¤ËØ¡¢Ôм¤ËØ£©µÄÏÔÖø×ª±ä£¬Ö¬ÁªËØË®Æ½ÍùÍù»á·ºÆðϽµ¡£
ÕâЩÇéÐÎÓëÈÑÉï´úлÐèÇóÏà¹Ø£¬µ«Ðè×¢ÖØ£¬ÈôÔÐÆÚÖ¬ÁªËØË®Æ½Òì³£¹ýµÍ£¨ÈçÅãͬ·ÊÅÖ»òÈÑÉïÌÇÄò²¡£©£¬¿ÉÄܼÓÖØÒȵºËضԿ¹£¬ÔöÌíÈÑÉï²¢·¢Ö¢Î£º¦£¬Ðèͨ¹ýºÏÀíÒûʳºÍÊʶÈÔ˶¯¾ÙÐе÷¿Ø¡£
Ö¬ÁªËؼì²âΪ´úл¿µ½¡ÆÀ¹À¿ª·¢ÐÂ;¾¶£¬ÊÇÆÀ¹ÀÒȵºËØÃô¸ÐÐÔÓëѪ¹Ü±£»¤¹¦Ð§µÄÒªº¦±ê¼ÇÎÔÚÕ¹ÍûÌÇÄò²¡¡¢ÐÄѪ¹Ü¼²²¡Î£º¦£¬ÆÀ¹À·ÊÅÖ¼°Ö¬·¾¸Î´úлΣº¦£¬¼à²â¸ÉԤЧ¹ûµÈ·½Ãæ¼ÛÖµÏÔÖø£¬¿ÉΪ¸ßΣÈËȺ¼°´úлÐÔ¼²²¡»¼ÕßÌṩÔö²¹ÕïÁÆÐÅÏ¢£¬Ö§³Ö¾«×¼¿µ½¡¹ÜÀíÓë¼²²¡·ÀÖΡ£
²Î¿¼ÎÄÏ×
£Û1£ÝSTRAUB L G,SCHERER P E£®Metabolic messengers£ºadiponectin[J].Nature Metabolism£¬2019£¬1(3):334.
£Û2£ÝºØË¼Ë¼,Ëïºèåû,ÕÅÏþÌ죬µÈ.Ö¬ÁªËؼì²âÔÚ2ÐÍÌÇÄò²¡ÕïÖÎÖеÄÑо¿Ï£Íû[J].ÖйúʵÑéÕï¶Ïѧ,2023,27(11):1374-1377.
£Û3£ÝWANG Y,KOH W P,SIM X£¬et al.Multiple biomarkers improved prediction for the risk of type 2 diabetes mellitus in Singapore Chinese men and women.[J].Diabetes & Metabolism Journal£¬2020£¬44(2):295.
£Û4£Ý³ÌÔÆÌÎ,Ñî¹âϼ,ÝþÔ¾¶°£¬µÈ.ÄòËáºÍÖ¬ÁªËØÓë¼±ÐÔÐ£ËÀ»¼ÕßÑ×ÐÔÒò×Óˮƽ¼°½éÈëÖÎÁƺ󱬷¢ÐÄÁ¦Ë¥½ßµÄ¹ØÏµ[J].ÖлªÍíÄêÐÄÄÔѪ¹Ü²¡ÔÓÖ¾,2023,25(7):704-707.
£Û5£ÝZHU Y£¬ZHANG J L£¬YAN X J£¬et al.Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention[J].Cardiovasc Diabetol£¬2022£¬21(1):186.
£Û6£ÝÂíÇ¿.IP6K1ÔÚ³¬ÖØ/·ÊÅÖÈËȺºÍ3T3L1ϸ°ûÖÐÓëÖ¬ÁªËصÄÏà¹ØÐÔ¼°Æä»úÖÆÑо¿[D].¹ãÖÝÄÏ·½Ò½¿Æ´óѧ,2019.
£Û7£ÝÕÅÓ굤£¬ÁõÊËȺ£¬·¶´æÏ¼£¬µÈ.ÒȸßѪÌÇËØÑùëÄ1ÊÜÌ弤¶¯¼Á¶Ô2ÐÍÌÇÄò²¡ºÏ²¢³¬ÖØ/·ÊÅÖ»¼Õß²î±ð²¿Î»Ö¬·¾ÂþÑܼ°¼¡È⺬Á¿µÄÓ°Ïì[J].ÄÏ·½Ò½¿Æ´óѧѧ±¨,2019£¬39(4)£º450-455.
£Û8£ÝIndulekha K,Surendar J,Anjana R M,et al.Metabolic obesity,adipocytokine-s,and inflammatory markers in Asian Indians¡ªCURES-124[J].Diabetes Technol Th-er,2015£¬17(2)£º134-141.
£Û9£Ý³Âٻ骣¬ÎéÀö£¬ÖìÒæÃñ£¬µÈ.·ÊÅÖÕßѪÇåÖ¬ÁªËØË®Æ½Óë´úл״̬µÄ¹ØÏµ[J].»ªÖпƼ¼´óѧѧ±¨£¨Ò½Ñ§°æ£©,2021£¬50(6)£º778-782.
£Û10£ÝYounossi ZM,Golabi P,Paik JM,et al.The global epidemiology of nonalcohol-ic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH):a systematic review[J].Hepatology,2023£¬77(4)£º1335-1347.
£Û11£ÝMavilia MG,Wu GY.Liver and serum adiponectin levels in nonalcoholic fatty liver disease[J].J Dig Dis,2021£¬22(4)£º214-221.
£Û12£ÝGozukara IO, Gozukara KH,Kucur SK,et al.Association of Glomerular Filtration Rate with Inflammation in Polycystic Ovary Syndrome.[J].Int J Fertil Steril,2015£¬9£º176-182.
£Û13£ÝÇdz̳̣¬Éòɽ÷.¶àÄÒÂѳ²×ÛºÏÕ÷»¼ÕßÄòËáÓëÖ¬ÁªËØÏà¹ØÐÔ×ÛÊö[J]. ÖйúÉúÓý¿µ½¡ÔÓÖ¾,2021£¬32(4)£º399-401.